International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-4 doi: 10.5281/zenodo.8179330
Original Article
A Prospective Study to Compare the Intensity-Modulated Radiation Therapy Planning by Flattening Filter Versus Flattening Filter free Beam in Carcinoma Larynx
 ,
 ,
 ,
 ,
 ,
Published
July 24, 2023
Abstract

Aim: The application of Flattening Filter Free (FFF) mode of a linear accelerator may be utilized in management of carcinoma larynx. The study aimed to compare the dosimetric analysis, toxicities of patients treated as well as response rate among them with Flattening Filter (FF) and FFF beam for Carcinoma Larynx.

Material and Methods: This study was conducted as prospective observational study on 60 cases of carcinoma larynx at our institute during study period of 2 years. Patients were randomly treated by either FF beam (30 patients) or FFF beam (30 patients) and dosimetric parameters for both plans were assessed along with response and toxicities at 0, 3, and 6 months.

Results: Two groups were comparable with respect to baseline variables and tumor characteristics (p>0.05). We found dose of radiation to parotid gland, spinal cord, and oral cavity to be significantly higher in FF treatment group as compared to FFF treatment group (p<0.05). Complete response to therapy was significantly better in FFF beam therapy as compared to FF beam therapy (p<0.05). Parotid toxicities were significantly higher in FF group at 6 months and toxicities for oral cavity and larynx were found significantly higher in FF group at 3 as well as 6 months (p<0.05).

Conclusions: IMRT is one of the common treatment modalities used in management of patients with carcinoma larynx. FFF beam is as effective as FF beam therapy in delivering the dose of radiation to the target tissue, with minimum radiation leakage to the adjacent normal tissues thereby reducing the risk of toxicities of organ at risks (parotid and oral cavity) and inducing better clinical response. The most beneficial character of FFF beam plan is clinically desirable and physically acceptable treatment plan at lower dose for target coverage and reduction of peripheral dose around target without compromising the quality of beam.

Recommended Articles
Loading Image...
Volume-4, Issue-4
Citations
2864 Views
205 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved